Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors

Inclusion Criteria

• Patients voluntarily participate in the study and should provide a written informed consent.
• Male or female patients ≥ 18 years of age.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Subjects with locally advanced or metastatic solid tumors failed to prior SOCs and no appropriate SOC to treat the current disease per investigator's judgement.
• Life expectancy ≥ 3 months.
• Subjects with adequate organ function.
• Men or women of childbearing potential (which refer to men or women who have not been surgically sterilized and pre-menopausal women) must use a highly effective method of contraception during the study and continue to take contraception measures for 6 months after the last dose of the study drug.

Exclusion Criteria

• Pregnant or lactating women.
• Prior systemic anticancer treatment within 5 half-lives or 4 weeks before the first dose (whichever is shorter).
• Active viral infection requiring systemic therapy during the screening period.
• Hypertension that cannot be well-controlled with medical treatment.
• Cardiovascular disease of clinical significance.
• Subjects with any active infection that requires anti-infective therapy judged by the investigators.
• Subjects are not suitable for participating the study judged by the investigators.
• Subjects with poor compliance, who are unwilling to or unable to follow study procedures.